Interview: Roberto Bellini, President & CEO, Bellus Health, Canada
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.
Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
275 Armand-Frappier Blvd.
Laval,
Quebec
Canada
H7V 4A7
Tel.: (450) 680-4500
Fax: (450) 680-4501
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Dr. John Sampalis, CEO of JSS talks about the impact that changes in the global R&D landscape have had on JSS, the role technology is playing in running an efficient…
Mark Nawacki, CEO and co-founder of Searchlight Pharma, affirms the company’s dedication to women’s health through a modern approach to current market trends. He underlines the company’s commitment to productive…
Dr. Janice E. Parente, president and founder of ethica CRO, explains what led her company to work with pharmaceutical companies internationally and how ethica CRO’s accreditations are an emblem of…
Linda Tibbits, general manager at Pierre Fabre Dermo-Cosmetics in Canada takes us back to the beginnings of the French company in the country, where its initial success was driven by…
Colette Rivet, executive director of the Cannabis Canada Association, leading Canadian licensed medical cannabis producers, talks regulatory challenges, upcoming opportunities, export ambitions and collaboration with the provincial and federal government…
Dr. Brian O’Rourke, president and CEO of CADTH, presents the organization’s main programs and the strategies it has put in place in order to ensure excellence in the future as…
Michael Rudnicki, chair of the Regenerative Medicine Alliance of Canada (RMAC) discusses the mandate of the newly established organization, the exciting potential of regenerative medicine, and Canada’s competitive edge in…
John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable enterprise with FDA approved products that are being…
Brian Lewis, president and CEO of MEDEC, speaks towards the importance of building a strong medical device ecosystem and the association’s collaboration with industry stakeholders to push advancements in terms…
Quebec’s Deputy Premier and Minister of Economy, Science and Innovation Dominique Anglade, who is also the Minister responsible for the Digital Strategy, shares the strategic significance of her portfolios to…
Michel Charbonneau, executive VP at Accord Healthcare Inc. touches upon the rapid evolution of the Canadian affiliate over the past five years, and the company’s commitment to bringing high-quality, innovative,…
Louis Pilon, president and CEO, highlights JAMP Pharma’s unique positioning as a Canadian generics company with one of the largest salesforce covering the whole Canadian market as well as the…
See our Cookie Privacy Policy Here
